How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,463 results for

Diarrhea Secondary to Medications

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update

Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update July 2018 In partnership withComparative Effectiveness Review Number 211 Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov and Patient (...) at: www.effectivehealthcare.ahrq.gov. Search on the title of the report. Persons using assistive technology may not be able to fully access information in this report. For assistance contact epc@ahrq.hhs.gov. Suggested citation: Donahue KE, Gartlehner G, Schulman ER, Jonas B, Coker-Schwimmer E, Patel SV, Weber RP, Lohr KN, Bann C, Viswanathan M. Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update. Comparative Effectiveness Review No. 211. (Prepared by the RTI International–University of North Carolina

2018 Effective Health Care Program (AHRQ)

2. Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their

by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Raltegravir + Lamivudine Drug: Raltegravir Raltegravir (1200 mg once a day) Drug: Lamivudine Lamivudine (300 mg once a day) Outcome Measures Go to Primary Outcome Measures : Therapeutic failure [ Time Frame: 48 weeks ] therapeutic failure at week 48, includes virological failure, change in treatment for any reason, consent withdrawal, loss to follow-up or death Secondary (...) Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug

2017 Clinical Trials

3. <b>Therapy of Small-cell Lung Cancer (SCLC) With a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan</b>. Full Text available with Trip Pro

Therapy of Small-cell Lung Cancer (SCLC) With a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan. Purpose: We evaluated a Trop-2-targeting antibody conjugated with SN-38 in metastatic small cell lung cancer (mSCLC) patients.Experimental Design: Sacituzumab govitecan was studied in patients with pretreated (median, 2; range, 1-7) mSCLC who received either 8 or 10 mg/kg i.v. on days 1 and 8 of 21-day cycles. The primary endpoints were safety (...) with sacituzumab govitecan in second-line patients who were sensitive to first-line therapy, but no difference between first-line chemosensitive versus chemoresistant patients in the overall population. There was a statistically significant higher OS in those patients who received prior topotecan versus no topotecan therapy in a small subgroup. Grade ≥3 adverse events included neutropenia (34%), fatigue (13%), diarrhea (9%), and anemia (6%). Trop-2 tumor staining was not required for patient selection

2017 Clinical Cancer Research

4. Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. (Abstract)

Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. Purpose Trop-2, expressed in most solid cancers, may be a target for antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC). We studied sacituzumab govitecan (IMMU-132), a Trop-2 ADC, for the targeting of SN-38. Patients and Methods We evaluated IMMU-132 in a single-arm multicenter trial in patients with pretreated metastatic NSCLC who received either 8 or 10 mg/kg (...) on days 1 and 8 of 21-day cycles. The primary end points were safety and objective response rate (ORR). Progression-free survival and overall survival were secondary end points. Results Fifty-four patients were treated. In the response-assessable study population (n = 47), which had a median of three prior therapies (range, two to seven), the ORR was 19%; median response duration, 6.0 months (95% CI, 4.8 to 8.3 months); and clinical benefit rate (complete response + partial response + stable disease

2017 Journal of Clinical Oncology

5. Ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic, or have medical contrai

Ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic, or have medical contrai October 2019 EUnetHTA Joint Action 3 WP4 1 EUnetHTA Joint Action 3 WP4 Version 1.0, 22/10/2019 Relative effectiveness assessment of pharmaceutical technologies USTEKINUMAB FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE (...) and Pharmaceutical Benefits Agency (TLV). Relative effectiveness assessment of pharmaceutical technologies. Ustekinumab for the treat- ment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic, or have medical contraindications to such therapies. EUnetHTA Project ID: PTJA07. 2019. PTJA07 - Ustekinumab for active ulcerative colitis October 2019 EUnetHTA Joint Action 3

2020 EUnetHTA

6. Dietary Therapy In Epilepsy Treatment (DIET-Trial): A Randomised Non Inferiority Trial Comparing KD, MAD & LGIT for Drug Resistant Epilepsy

Dietary Therapy In Epilepsy Treatment (DIET-Trial): A Randomised Non Inferiority Trial Comparing KD, MAD & LGIT for Drug Resistant Epilepsy Dietary Therapy In Epilepsy Treatment (DIET-Trial): A Randomised Non Inferiority Trial Comparing KD, MAD & LGIT for Drug Resistant Epilepsy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study (...) Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Dietary Therapy In Epilepsy Treatment (DIET-Trial): A Randomised Non Inferiority Trial Comparing KD, MAD & LGIT for Drug Resistant Epilepsy (DIET) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov

2016 Clinical Trials

7. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures

with partial/full funding 34 from pharmaceutical companies on the psoriasis disease state or psoriasis drugs in 35 development or FDA-approved. 36 Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy, and alternative medicine modalities for psoriasis severity measures-manuscript draft Page 3 of 95 Draft guideline recommendations were developed through a collaborative approach 37 between conflicted and non-conflicted section leaders. Initial recommendations (...) of psoriasis with topical therapy, and alternative medicine modalities for psoriasis severity measures-manuscript draft Page 6 of 95 recognition of psoriasis as a chronic, multisystem inflammatory disorder is imperative to 102 optimize management and reduce comorbidities. 103 Topical medications are the most common agents used to treat mild to moderate 104 psoriasis patients. They are frequently used as adjunctive therapies for patients on 105 phototherapy, systemic, or biologic therapy. Alternative

2020 American Academy of Dermatology

8. Clinical Trial of a New Software ENgine for the Assessment & Optimization of Drug and Non-drug Therapy in Older peRsons

Clinical Trial of a New Software ENgine for the Assessment & Optimization of Drug and Non-drug Therapy in Older peRsons Clinical Trial of a New Software ENgine for the Assessment & Optimization of Drug and Non-drug Therapy in Older peRsons - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Clinical Trial of a New Software ENgine for the Assessment & Optimization of Drug and Non-drug Therapy in Older peRsons (SENATOR) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02097654 Recruitment Status : Completed

2014 Clinical Trials

9. [Clinical effect of Saccharomyces boulardii powder combined with azithromycin sequential therapy in treatment of children with diarrhea secondary to Mycoplasma pneumoniae pneumonia]. (Abstract)

[Clinical effect of Saccharomyces boulardii powder combined with azithromycin sequential therapy in treatment of children with diarrhea secondary to Mycoplasma pneumoniae pneumonia]. To investigate the clinical effect of Saccharomyces boulardii powder combined with azithromycin sequential therapy in the treatment of children with diarrhea secondary to Mycoplasma pneumoniae pneumonia.A total of 88 children with diarrhea secondary to Mycoplasma pneumoniae pneumonia between June 2015 and March (...) frequency compared with the control group (P<0.05). The study group had a significantly lower rate of intestinal dysbacteriosis than the control group (P<0.05). There was no significant difference in the incidence of adverse events between the two groups (P>0.05).In the treatment of children with diarrhea secondary to Mycoplasma pneumoniae pneumonia, Saccharomyces boulardii powder combined with azithromycin sequential therapy can improve clinical symptoms, shorten the length of hospital stay, reduce

2018 Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics Controlled trial quality: uncertain

10. Diarrhea Secondary to Medications

to Medications Diarrhea Secondary to Medications Aka: Diarrhea Secondary to Medications , Drug-Induced Diarrhea , Medication-Induced Diarrhea From Related Chapters II. Causes: Medication Class See s (e.g. ) s Amoxicillan-Clavulanate ( ) Chemotherapeutic agents Antiinflammatory medications S s ( ) Antihypertensives s s ( ) May cause a sprue-like not seen with other s Endocrine agents ( ) ( ) ( ) Gastrointestinal Agents or calcium containing s s (e.g. , senna) s (e.g. ) s (e.g. ) Metoclopramide (Reglan (...) Diarrhea Secondary to Medications Diarrhea Secondary to Medications Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Diarrhea Secondary

2018 FP Notebook

11. Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. Full Text available with Trip Pro

Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. Low-dose lansoprazole has not been intensively evaluated for its efficacy in the prevention of recurrent gastric or duodenal ulcers in patients receiving long-term non-steroidal anti-inflammatory drug (NSAID) therapy for pain relief (...) -term follow-up study showed an acceptable safety profile for low-dose lansoprazole therapy, with diarrhea as the most frequent adverse event.Lansoprazole was superior to gefarnate in reducing the risk of gastric or duodenal ulcer recurrence in patients with a definite history of gastric or duodenal ulcers who required long-term NSAID therapy.

2012 Journal of gastroenterology Controlled trial quality: predicted high

12. Covid-19 drug vignettes: Azithromycin

Covid-19 drug vignettes: Azithromycin Drug vignettes: Azithromycin - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website Drug vignettes: Azithromycin May 13, 2020 Robin E Ferner*, Jeffrey K Aronson On behalf of the Oxford COVID-19 Evidence Service Team Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences University of Oxford *University of Birmingham Correspondence (...) impairment. Known and potential adverse effects The and the list many adverse drug reactions. Common or very common adverse reactions include diarrhoea, nausea, vomiting, headache, and fatigue. Uncommon or rare adverse effects and adverse reactions include gastritis, dyspnoea, reduced white cell count, abnormal liver function tests, anxiety and agitation, rashes, and arthralgia. The reaction frequencies are defined according to the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10

2020 Oxford COVID-19 Evidence Service

13. Covid-19: Drug vignettes: Interferons

Covid-19: Drug vignettes: Interferons Drug vignettes: Interferons - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website Drug vignettes: Interferons August 6, 2020 Jeffrey K Aronson, Nicholas DeVito, Annette Plüddemann, Robin E Ferner* † On behalf of the Oxford COVID-19 Evidence Service Team Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences University of Oxford *University (...) and not necessarily those of the host institution, the NHS, the NIHR, or the Department of Health and Social Care. The views are not a substitute for professional medical advice. Most viewed COVID-19 podcast © 2020 Centre for Evidence-Based Medicine

2020 Oxford COVID-19 Evidence Service

14. Covid-19: Drug vignettes: Remdesivir

Covid-19: Drug vignettes: Remdesivir Drug vignettes: Remdesivir - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website Drug vignettes: Remdesivir August 10, 2020 Robin E Ferner* † , Jeffrey K Aronson On behalf of the Oxford COVID-19 Evidence Service Team Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford *University of Birmingham † University College (...) to day 29, recovery having been defined in the protocol as “the first day on which the subject satisfies one of the following three categories from the ordinal scale: 1) Hospitalized, not requiring supplemental oxygen – no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Not hospitalized, no limitations on activities.” Mortality at 28 days and duration of hospital stay were two of 28 secondary outcomes [ ]. Selected baseline

2020 Oxford COVID-19 Evidence Service

15. Rifamycin SV-MMX® for treatment of travelers' diarrhea: equally effective as ciprofloxacin and not associated with the acquisition of multi-drug resistant bacteria. Full Text available with Trip Pro

Rifamycin SV-MMX® for treatment of travelers' diarrhea: equally effective as ciprofloxacin and not associated with the acquisition of multi-drug resistant bacteria. The novel oral antibiotic formulation Rifamycin SV-MMX®, with a targeted delivery to the distal small bowel and colon, was superior to placebo in treating travellers' diarrhea (TD) in a previous study. Thus, a study was designed to compare this poorly absorbed antibiotic with the systemic agent ciprofloxacin.In a randomized double (...) were collected at the baseline visit and the end of treatment visit.Median TLUS in the RIF-MMX group was 42.8 h versus 36.8 h in the ciprofloxacin group indicating non-inferiority of RIF-MMX to ciprofloxacin (P = 0.0035). Secondary efficacy endpoint results including clinical cure rate, treatment failure rate, requirement of rescue therapy as well as microbiological eradication rate confirmed those of the primary analysis indicating equal efficacy for both compounds. While patients receiving

2018 Journal of Travel Medicine Controlled trial quality: predicted high

16. Update on COVID-19 epidemiology and impact on medical care in children: April 2020

) and underline the primary importance of meticulous environmental cleaning [ ] . Managing children and youth infected with symptomatic COVID-19 No treatment for COVID-19 is proven to be effective at the present time, and early reports from trials of hydroxychloroquine in adults have not demonstrated any beneficial effect on morbidity or mortality [ ] . Several Canadian universities, research centres, and medical organizations have recommended against using of off-label, investigational therapies (...) Update on COVID-19 epidemiology and impact on medical care in children: April 2020 Update on COVID-19 epidemiology and impact on medical care in children: April 2020Update on COVID-19 epidemiology and impact on medical care in children: April 2020 | Canadian Paediatric Society A home for paediatricians. A voice for children and youth. Current: Update on COVID-19… Practice Point Update on COVID-19 epidemiology and impact on medical care in children: April 2020 Posted: Apr 29, 2020 The Canadian

2020 Canadian Paediatric Society

17. Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs

throughout the trial, and average drinks per day. To evaluate changes in serum electrolytes before and after administration of Eenterade®. To assess intravenous fluid requirement and/or hospitalization for dehydration secondary to diarrhea between control observation period and active Enterade® period. To evaluate difference in utilization of standard-of-care anti-diarrheal medications between control observation period and Enterade® period. To compare subjective feeling of bloating and flatulence before (...) Medical Food/Drink Additional relevant MeSH terms: Layout table for MeSH terms Syndrome Neoplasms Diarrhea Neuroendocrine Tumors Carcinoid Tumor Malignant Carcinoid Syndrome Serotonin Syndrome Digestive System Neoplasms Gastrointestinal Neoplasms Disease Pathologic Processes Signs and Symptoms, Digestive Signs and Symptoms Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms, Nerve Tissue Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Drug

2018 Clinical Trials

18. AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D) Full Text available with Trip Pro

Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D) x Walter Smalley Affiliations Department of Medicine, Division of Gastroenterology, Vanderbilt University School of Medicine, Nashville, Tennessee Veterans Affairs Tennessee Valley Health Care System, Nashville, Tennessee 1 , 2 , x Corinna Falck-Ytter Affiliations Departments of Medicine and Gastroenterology, Case Western Reserve University, Cleveland, Ohio Veterans Affairs (...) Affiliations Departments of Medicine and Gastroenterology, Case Western Reserve University, Cleveland, Ohio Veterans Affairs Northeast Ohio Health System, Cleveland, Ohio 3 , 4 DOI: | Publication History Published online: July 11, 2019 Expand all Collapse all Article Outline Abbreviations used in this paper: ( ), ( ), ( ), ( ), ( ), ( ), ( ) This document presents the official recommendations of the American Gastroenterological Association (AGA) on the Laboratory Evaluation of Functional Diarrhea

2019 American Gastroenterological Association Institute

19. Management of Cancer Medication-Related Infusion Reactions

Advisors who reviewed the patient information sheet Expert Reviewers Dr. Peter Vadas, Head, Division of Allergy and Clinical Immunology, St. Michael’s Hospital Dr. Baruch Jakubovic, Division of Clinical Immunology, Department of Medicine, University of Toronto Dr. Silvana Spadafora, Medical Oncologist/Chief of Staff, Algoma District Cancer Program, Sault Area Hospital Dana Root, Lead Oncology Pharmacist, Windsor Regional Hospital Diana Incekol, Advanced Practice Nurse Educator, Princess Margaret Cancer (...) with a drug’s mechanism of action. 1,2 The incidence of IRs varies depending on the anticancer agent used. In some cases, the incidence of reactions may be low but the risk for potentially life-threatening reactions exists. 2,3 Most IRs occur within the first hour of either the first or second administration of an intravenous anticancer medication; therefore, careful monitoring during infusion initiation is necessary to detect potential IRs and manage accordingly. 3 In cases where IRs may be prevented

2019 Cancer Care Ontario

20. Covid-19: Guidance review for emergency medical dispatch centres

England, (27) the Pre-Hospital Emergency Care Council of Ireland, (26) the Indian Ministry of Health, (29) the Chinese National Health Commission, (28) the European Society for Emergency Medicine, (19) the Collaborative Coalition for International Public Safety, (18) and the International Liaison Committee on Resuscitation. (11) Review of guidance for the operation of emergency medical dispatch centres Health Information and Quality Authority Page 8 of 82 Guidance content: relevance Seven documents (...) Covid-19: Guidance review for emergency medical dispatch centres Review of guidance for the operation of emergency medical dispatch centres Health Information and Quality Authority Page 1 of 82 Review of guidance for the operation of emergency medical dispatch centres in the context of COVID-19 and beyond 4 September 2020 Review of guidance for the operation of emergency medical dispatch centres Health Information and Quality Authority Page 2 of 82 The Health Information and Quality Authority

2020 Health Information and Quality Authority

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>